Table 1:

Clinical Trials Targeting KEAP1/NRF2 Mutant Tumors

Trial	Drug	Study Type	Inclusion	Intervention	Primary Outcomes
KEAPSAKE NCT04265534	CB-839 (Telaglenastat)	Phase 2 Randomized placebo controlled	Metastatic NSCLC with mutation in KEAP1, NRF2, or LKB1	Pembrolizumab + Carboplatin + Pemetrexed +/− CB-839	Progression Free Survival Safety and Tolerability Dosing
BeGIN NCT03872427	CB-839	Phase 2 Open label single arm	Advanced tumor with mutation in NF1, KEAP1, or LKB1	CB-839	Best Overall Response Rate
NCT04471415	DRP-104 (Sirpiglenastat)	Phase 1 and 2a Dose Escalation Dose expansion	Advanced NSCLC with mutation in KEAP1, NRF2, or LKB1 and already received 1st line therapy	DRP-104 + Atezolizumab	Maximum tolerated dose Area under plasma concentration Cmax of DRP-104
NCT02417701	Sapanisertib	Phase 2 Randomized open label	Stage IV or recurrent SCC with KEAP1 or NRF2 mutation	Docetaxel + Sapanisertib	Progression Free Survival